| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S0033291711002157 |
| P698 | PubMed publication ID | 22030695 |
| P50 | author | David Collier | Q21094975 |
| Grainne M. McAlonan | Q48969560 | ||
| P2093 | author name string | Z Chen | |
| M Li | |||
| Y Wang | |||
| T Li | |||
| Q Wang | |||
| Z He | |||
| L Jiang | |||
| Q Gong | |||
| X Ma | |||
| P C Sham | |||
| C Cheung | |||
| W Deng | |||
| S E Chua | |||
| P2860 | cites work | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| Schizophrenia: more dopamine, more D2 receptors | Q24630726 | ||
| A review of MRI findings in schizophrenia | Q24657354 | ||
| Structural asymmetries in the human brain: a voxel-based statistical analysis of 142 MRI scans | Q28215005 | ||
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| Dopaminergic dysfunction in schizophrenia: salience attribution revisited. | Q30475711 | ||
| MR volumetric analysis of the human basal ganglia: normative data | Q30608740 | ||
| Do we still believe in the dopamine hypothesis? New data bring new evidence | Q30906669 | ||
| Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies | Q31023592 | ||
| Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies | Q31043017 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia | Q33223628 | ||
| Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings | Q33425487 | ||
| The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review. | Q33494667 | ||
| The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia | Q33537860 | ||
| Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 | ||
| Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia | Q34383654 | ||
| Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study | Q34392600 | ||
| Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia | Q34482389 | ||
| An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone | Q34514487 | ||
| Behavioral dopamine signals | Q34614382 | ||
| Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate | Q34753882 | ||
| Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study | Q34871391 | ||
| Longitudinal stability of MRI for mapping brain change using tensor-based morphometry | Q35928408 | ||
| Dopamine and adult neurogenesis | Q36652288 | ||
| Dopamine hypothesis of schizophrenia: making sense of it all. | Q36946141 | ||
| Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia | Q37441628 | ||
| The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics | Q42436896 | ||
| Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. | Q44845263 | ||
| Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone | Q45288090 | ||
| Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. | Q45939068 | ||
| Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended | Q46543898 | ||
| Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. | Q46549241 | ||
| A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition. | Q46567494 | ||
| Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia | Q46875969 | ||
| Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task | Q47293404 | ||
| Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected | Q47334156 | ||
| Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative | Q48102710 | ||
| Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia | Q48143027 | ||
| Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug | Q48242740 | ||
| Cerebral asymmetry in patients with schizophrenia: a voxel-based morphometry (VBM) and diffusion tensor imaging (DTI) study | Q48371759 | ||
| Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. | Q48373158 | ||
| Left-right asymmetry of striatal dopamine D2 receptors | Q48387496 | ||
| Localization of cerebral functional deficits in treatment-naive, first-episode schizophrenia using resting-state fMRI. | Q48388886 | ||
| Frontal lobe volumes in schizophrenia: effects of stage and duration of illness | Q48450151 | ||
| Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia | Q48472115 | ||
| Volumetric asymmetry and differential aging effect of the human caudate nucleus in normal individuals: a prospective MR imaging study. | Q48493030 | ||
| A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia. | Q48499474 | ||
| Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects | Q48607713 | ||
| Volume increases in striatum associated with positive symptom reduction in schizophrenia: a preliminary observation | Q48759663 | ||
| Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia | Q48905087 | ||
| Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. | Q48960835 | ||
| Anomalous cerebral asymmetry in patients with schizophrenia demonstrated by voxel-based morphometry. | Q51732761 | ||
| Age-related cognitive deficits mediated by changes in the striatal dopamine system. | Q52028033 | ||
| Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics | Q55969829 | ||
| Brain Volume Changes After Withdrawal of Atypical Antipsychotics in Patients With First-Episode Schizophrenia | Q60610017 | ||
| Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs | Q72692455 | ||
| Time course for antipsychotic treatment response in first-episode schizophrenia | Q83058853 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| putamen | Q550934 | ||
| P304 | page(s) | 1475-1483 | |
| P577 | publication date | 2011-10-26 | |
| P1433 | published in | Psychological Medicine | Q7256364 |
| P1476 | title | Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment | |
| P478 | volume | 42 |
| Q58712902 | A Perspective of the Cross-Tissue Interplay of Genetics, Epigenetics, and Transcriptomics, and Their Relation to Brain Based Phenotypes in Schizophrenia |
| Q33761026 | A multi-scanner study of subcortical brain volume abnormalities in schizophrenia |
| Q98286217 | Asphyxia at birth affects brain structure in patients on the schizophrenia-bipolar disorder spectrum and healthy participants |
| Q64298943 | Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents: A Voxelwise and Genome-Wide Association Study |
| Q37627386 | Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. |
| Q55437545 | Classification of multi-site MR images in the presence of heterogeneity using multi-task learning☆. |
| Q47142790 | Decreased Left Putamen and Thalamus Volume Correlates with Delusions in First-Episode Schizophrenia Patients |
| Q91899116 | Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naive, first-episode schizophrenia: Results from two independent study samples |
| Q50556051 | First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia. |
| Q92518217 | Functional brain networks in never-treated and treated long-term Ill schizophrenia patients |
| Q28587963 | Genome-wide association study of paliperidone efficacy |
| Q34701163 | Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. |
| Q36790073 | Larger putamen size in antipsychotic-naïve individuals with schizotypal personality disorder |
| Q89314064 | Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies |
| Q38086645 | Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment |
| Q64944506 | Progressive Grey Matter Volume Changes in Patients with Schizophrenia over 6 Weeks of Antipsychotic Treatment and Their Relationship to Clinical Improvement. |
| Q92060742 | Putamen gray matter volumes in neuropsychiatric and neurodegenerative disorders |
| Q30711211 | Similar and different gray matter deficits in schizophrenia patients and their unaffected biological relatives |
| Q90256318 | Subcortical Brain Volume Abnormalities in Individuals With an At-risk Mental State |
| Q23747506 | Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium |
| Q34020393 | The polymorphism of YWHAE, a gene encoding 14-3-3epsilon, and brain morphology in schizophrenia: a voxel-based morphometric study |
Search more.